Canada · Health Canada Drug Product Database
GARDASIL 9
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 92136
- DIN
- 02437058
- Form
- Suspension
- Company as listed by source
- MERCK CANADA INC
- Source status
- Marketed (2015-03-18)
- Source last updated
- 2026-08-19
Source-listed ingredients
- RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 18 L1 PROTEIN — 40 MCG — per 0.5 ML
- RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 31 L1 PROTEIN — 20 MCG — per 0.5 ML
- RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 33 L1 PROTEIN — 20 MCG — per 0.5 ML
- RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 45 L1 PROTEIN — 20 MCG — per 0.5 ML
- RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 52 L1 PROTEIN — 20 MCG — per 0.5 ML
- RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 58 L1 PROTEIN — 20 MCG — per 0.5 ML
- RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 6 L1 PROTEIN — 30 MCG — per 0.5 ML
- RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 11 L1 PROTEIN — 40 MCG — per 0.5 ML
- RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 16 L1 PROTEIN — 60 MCG — per 0.5 ML
These values do not establish equivalence or a dose recommendation.
Packages
- 0.5ml
Source and coverage
Open Health Canada Drug Product Database →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse Canada records →